(Q36945941)

17 August 2017

1 reference

title

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal (English)

1 reference

17 August 2017

0 references

M J Sumner

1

1 reference

17 August 2017

B D Geldziler

series ordinal

2

1 reference

17 August 2017

M Pedersen

series ordinal

3

1 reference

17 August 2017

S Seremetis

series ordinal

4

1 reference

17 August 2017

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

13

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

451-461

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

17 August 2017

1 reference

Acquired haemophilia: experiences with a standardized approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Transfusion medicine. First of two parts--blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Thrombogenicity of prothrombin complex concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Virus safety of prothrombin complex concentrates and factor IX concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Potential role for rFVIIa in transfusion medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Platelet activity of high-dose factor VIIa is independent of tissue factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Successful treatment of acquired factor VIII inhibitor with cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Successful treatment of acquired factor VIII deficiency in a child using activated factor VII concentrates: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Effective treatment with recombinant factor VIIa of severe bleeding due to acquired factor VIII inhibitor and acquired thrombocytopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Experience with use of recombinant activated factor VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Recombinant activated factor VII therapy in acquired hemophilia of the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired haemophilia in the elderly is a severe disease: report of five new cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Recombinant FVIIa in the treatment of bleeding in acquired hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Anti-inhibitor coagulant complex for the rescue therapy of acquired inhibitors to factor VIII: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired haemophilia in a patient with gram-negative urosepsis and bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired inhibitor of the intrinsic pathway in a non-haemophilic patient. Control of bleeding by recombinant factor viia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Postpartum inhibitor to factor VIII: treatment with high-dose immunoglobulin and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Severe acquired hemophilia A successfully treated with activated recombinant human factor VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Successful steroid pulse treatment in childhood acquired haemophilia with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Severe aquired haemophilia A treated with recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

Surgery-associated acquired hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01474.X

10.1111/J.1365-2516.2007.01474.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference